Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Almudena Zapatero

Showing results (41-50 of 61) with videos related to

Pageof 7
Sort By:
Practical Radiation Oncology|June 30, 2024
A Phase II Trial of Stereotactic Body Radiation Therapy and Androgen Deprivation for Oligometastases in Prostate Cancer (SBRT-SG 05)Antonio J Conde-Moreno, Fernando López-Campos, Asunción Hervás, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|October 13, 2022
Recommendations for radiation therapy in oligometastatic prostate cancer: An ESTRO-ACROP Delphi consensusThomas Zilli, Vérane Achard, Alan Dal Pra, et al.
European Urology|September 20, 2024
Testosterone Recovery Following Androgen Suppression and Prostate Radiotherapy (TRANSPORT): A Pooled Analysis of Five Randomized Trials from the Meta-Analysis of Randomized Trials in Cancer of the Prostate (MARCAP) ConsortiumWee Loon Ong, Tahmineh Romero, Soumyajit Roy, et al.
European Urology Oncology|January 21, 2026
Health-related Quality of Life Outcomes of Salvage Metastasis-directed Treatment Versus Elective Nodal Treatment for Oligorecurrent Nodal Prostate Cancer: A Secondary Analysis of the Phase 2, Open-label PEACE V-STORM Randomized TrialThomas Zilli, Shankar Siva, Sigmund Brabrand, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|April 27, 2022
Oligorecurrent nodal prostate cancer: Radiotherapy quality assurance of the randomized PEACE V-STORM phase II trialVérane Achard, Maud Jaccard, Frederik Vanhoutte, et al.
The Lancet. Oncology|May 8, 2025
Salvage metastasis-directed therapy versus elective nodal radiotherapy for oligorecurrent nodal prostate cancer metastases (PEACE V-STORM): a phase 2, open-label, randomised controlled trialPiet Ost, Shankar Siva, Sigmund Brabrand, et al.
European Urology Focus|January 2, 2021
The Multicenter, Randomized, Phase 2 PEACE V-STORM Trial: Defining the Best Salvage Treatment for Oligorecurrent Nodal Prostate Cancer MetastasesThomas Zilli, Piet Dirix, Reino Heikkilä, et al.
European Urology Oncology|October 11, 2023
PEACE V-Salvage Treatment of OligoRecurrent nodal prostate cancer Metastases (STORM): Acute Toxicity of a Randomized Phase 2 TrialPiet Ost, Shankar Siva, Sigmund Brabrand, et al.
The Lancet. Oncology|March 1, 2023
Metastases-directed stereotactic body radiotherapy in combination with targeted therapy or immunotherapy: systematic review and consensus recommendations by the EORTC-ESTRO OligoCare consortiumStephanie G C Kroeze, Matea Pavic, Karin Stellamans, et al.
The Lancet. Oncology|January 20, 2022
Androgen deprivation therapy use and duration with definitive radiotherapy for localised prostate cancer: an individual patient data meta-analysisAmar U Kishan, Yilun Sun, Holly Hartman, et al.
Pageof 7

Showing results (41-50 of 61) with videos related to

Sort By:
Pageof 7
Practical Radiation Oncology|June 30, 2024
A Phase II Trial of Stereotactic Body Radiation Therapy and Androgen Deprivation for Oligometastases in Prostate Cancer (SBRT-SG 05)Antonio J Conde-Moreno, Fernando López-Campos, Asunción Hervás, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|October 13, 2022
Recommendations for radiation therapy in oligometastatic prostate cancer: An ESTRO-ACROP Delphi consensusThomas Zilli, Vérane Achard, Alan Dal Pra, et al.
European Urology|September 20, 2024
Testosterone Recovery Following Androgen Suppression and Prostate Radiotherapy (TRANSPORT): A Pooled Analysis of Five Randomized Trials from the Meta-Analysis of Randomized Trials in Cancer of the Prostate (MARCAP) ConsortiumWee Loon Ong, Tahmineh Romero, Soumyajit Roy, et al.
European Urology Oncology|January 21, 2026
Health-related Quality of Life Outcomes of Salvage Metastasis-directed Treatment Versus Elective Nodal Treatment for Oligorecurrent Nodal Prostate Cancer: A Secondary Analysis of the Phase 2, Open-label PEACE V-STORM Randomized TrialThomas Zilli, Shankar Siva, Sigmund Brabrand, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|April 27, 2022
Oligorecurrent nodal prostate cancer: Radiotherapy quality assurance of the randomized PEACE V-STORM phase II trialVérane Achard, Maud Jaccard, Frederik Vanhoutte, et al.
The Lancet. Oncology|May 8, 2025
Salvage metastasis-directed therapy versus elective nodal radiotherapy for oligorecurrent nodal prostate cancer metastases (PEACE V-STORM): a phase 2, open-label, randomised controlled trialPiet Ost, Shankar Siva, Sigmund Brabrand, et al.
European Urology Focus|January 2, 2021
The Multicenter, Randomized, Phase 2 PEACE V-STORM Trial: Defining the Best Salvage Treatment for Oligorecurrent Nodal Prostate Cancer MetastasesThomas Zilli, Piet Dirix, Reino Heikkilä, et al.
European Urology Oncology|October 11, 2023
PEACE V-Salvage Treatment of OligoRecurrent nodal prostate cancer Metastases (STORM): Acute Toxicity of a Randomized Phase 2 TrialPiet Ost, Shankar Siva, Sigmund Brabrand, et al.
The Lancet. Oncology|March 1, 2023
Metastases-directed stereotactic body radiotherapy in combination with targeted therapy or immunotherapy: systematic review and consensus recommendations by the EORTC-ESTRO OligoCare consortiumStephanie G C Kroeze, Matea Pavic, Karin Stellamans, et al.
The Lancet. Oncology|January 20, 2022
Androgen deprivation therapy use and duration with definitive radiotherapy for localised prostate cancer: an individual patient data meta-analysisAmar U Kishan, Yilun Sun, Holly Hartman, et al.
Pageof 7